Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Emergent BioSolutions Inc is a drug manufacturers—specialty & generic business based in the US. Emergent BioSolutions shares (EBS) are listed on the NYSE and all prices are listed in US Dollars. Emergent BioSolutions employs 1,834 staff and has a trailing 12-month revenue of around USD$1.3 billion.
Since the stock market crash in March caused by coronavirus, Emergent BioSolutions's share price has had significant positive movement.
Its last market close was USD$86.72, which is 23.96% up on its pre-crash value of USD$65.94 and 87.02% up on the lowest point reached during the March crash when the shares fell as low as USD$46.37.
If you had bought USD$1,000 worth of Emergent BioSolutions shares at the start of February 2020, those shares would have been worth USD$873.14 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,526.27.
|Latest market close||USD$86.72|
|52-week range||USD$48.12 - USD$137.61|
|50-day moving average||USD$103.9974|
|200-day moving average||USD$92.7212|
|Wall St. target price||USD$112.29|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$3.191|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-23)||8.85%|
|1 month (2020-10-30)||-3.61%|
|3 months (2020-08-28)||-26.25%|
|6 months (2020-05-29)||3.87%|
|1 year (2019-11-29)||58.08%|
|2 years (2018-11-30)||19.06%|
|3 years (2017-11-30)||97.40%|
|5 years (2015-11-30)||130.21%|
Valuing Emergent BioSolutions stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Emergent BioSolutions's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Emergent BioSolutions's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 31x. In other words, Emergent BioSolutions shares trade at around 31x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Emergent BioSolutions's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.55. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Emergent BioSolutions's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Emergent BioSolutions's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$408.6 million.
The EBITDA is a measure of a Emergent BioSolutions's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$1.3 billion|
|Operating margin TTM||23.8%|
|Gross profit TTM||USD$483.1 million|
|Return on assets TTM||7.83%|
|Return on equity TTM||15.57%|
|Market capitalisation||USD$5.1 billion|
TTM: trailing 12 months
There are currently 2.2 million Emergent BioSolutions shares held short by investors – that's known as Emergent BioSolutions's "short interest". This figure is 12.7% down from 2.5 million last month.
There are a few different ways that this level of interest in shorting Emergent BioSolutions shares can be evaluated.
Emergent BioSolutions's "short interest ratio" (SIR) is the quantity of Emergent BioSolutions shares currently shorted divided by the average quantity of Emergent BioSolutions shares traded daily (recently around 582590.15957447). Emergent BioSolutions's SIR currently stands at 3.76. In other words for every 100,000 Emergent BioSolutions shares traded daily on the market, roughly 3760 shares are currently held short.
However Emergent BioSolutions's short interest can also be evaluated against the total number of Emergent BioSolutions shares, or, against the total number of tradable Emergent BioSolutions shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Emergent BioSolutions's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Emergent BioSolutions shares in existence, roughly 40 shares are currently held short) or 0.0578% of the tradable shares (for every 100,000 tradable Emergent BioSolutions shares, roughly 58 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Emergent BioSolutions.
Find out more about how you can short Emergent BioSolutions stock.
We're not expecting Emergent BioSolutions to pay a dividend over the next 12 months.
Over the last 12 months, Emergent BioSolutions's shares have ranged in value from as little as $48.12 up to $137.61. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Emergent BioSolutions's is 1.4109. This would suggest that Emergent BioSolutions's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard a combination drug-device auto injector product candidate. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; and ADENOVIRUS 4/7. Further, the company offers other discovery and preclinical product candidates addressing PHTs, including viral hemorrhagic fevers caused by Ebola, Marburg, Sudan, and Lassa viruses; diarrheal disease caused by Shigella; and heat-labile toxin producing enterotoxigenic Escherichia coli, etc. Additionally, it offers FLU-IGIV to treat Influenza A infection; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract development and manufacturing services to pharma and biotech industries, and government agencies/non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.